PHAR News & Analysis
2 articles
Market Mood
Pharvaris Stock Rating Reiterated by H.C. Wainwright Amid Progress
H.C. Wainwright has reiterated its rating on Pharvaris, citing progress in regulatory matters. The firm has previously provided various outlooks but emphasizes its confidence in the company's advancements. This support could influence investor perceptions and trading strategies. For investors, ongoing regulatory progress may enhance the company's market position, affecting Pharvaris's (PHAR) stock performance.
Read More: Pharvaris Stock Rating Reiterated by H.C. Wainwright Amid Progress
Trump Administration Announces New Tariffs on Pharmaceuticals
The Trump administration announced new tariffs on pharmaceuticals while also rolling back levies on certain metals. These changes aim to simplify duties affecting trade relations and may impact market prices for pharmaceutical companies. The specific tariff rates on pharmaceuticals were not detailed in the announcement. This decision could influence trading volumes for affected sectors as companies respond to the adjusted trade conditions.
Read More: Trump Administration Announces New Tariffs on Pharmaceuticals